A Summary of Clinical Evidence
|
|
- Meagan Newman
- 5 years ago
- Views:
Transcription
1 A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS
2 Table of Contents Overview of HIV...3 Natural History and Immunopathogenesis of HIV-1 Infection Treatment of HIV...6 Screening recommendations...7 A History of HIV diagnostic tests...7 Alere Determine HIV 1/2 Ag/Ab Combo...8 Alere Determine HIV 1/2 Ag/Ab Combo: HIV-1 Clinical Data...9 Alere Determine HIV 1/2 Ag/Ab Combo: HIV-1 Preclinical Data...10 Published Studies Summary of device description and biological principle of the procedure...13 Product Information...14 References...15
3 Alere Determine HIV-1/2 Ag/Ab Combo 3 Overview of HIV (Human Immunodeficiency Virus) 1.2 Million According to the CDC, there were almost 1.2 million people (1 out of every 250) in U.S. that were HIV positive in HIV, or human immunodeficiency virus, is the virus that causes AIDS. It attacks the immune system by destroying CD4 positive (CD4+) T cells that are vital to fighting off infection. HIV belongs to a class of viruses known as retroviruses. Within that class, HIV is in the lentivirus subgroup, the members of which are known for having a long time period between initial infection and the beginning of serious symptoms. This is why there are many people who are unaware of their HIV infection and can unknowingly spread the virus to others. Early detection of HIV infection is critical in helping to minimize further transmission of the disease. The four main routes of infection are unsafe sex, contaminated needles, breast milk from an infected mother, and birth to an infected mother. Transmission through blood and blood products has largely been eliminated as a result of screening of blood donations. According to the CDC, there were almost 1.2 million people (1 out of every 250) in U.S. that were HIV positive in % (nearly ¼ of million) are not aware of their positive status. 1 This group is responsible for an estimated 2/3 (54-70%) of all new HIV infections. 2
4 Alere Determine HIV-1/2 Ag/Ab Combo 4 Natural History and Immunopathogenesis of HIV-1 Infection 3 Laboratory Markers Infection Stage Viral RNA + Gag p24 antigen + ELISA + Western Blot ± Viral Load (virions/ml of plasma) Viral Load Days since infection Data taken from Cohen S.M. et al. The Detection of Acute HIV-1 Infection. Journal of Infectious Disease, ; s The progression of HIV-1 infection can be depicted as discrete stages based on the viral load and the sequential appearance of different markers at any given point in time. How HIV infection can be detected during each of these phases will differ. Only certain tests are able to detect the different markers present during these phases. The actual timing for each of these key stages of HIV infection will vary for any individual patient. Immediately following initial exposure, HIV-1 seeks out sanctuary in the mucosal tissues where it continues the process of replication. This period, after infection and prior to detection of viral RNA, is defined as the eclipse phase. During this phase (which varies from 7 to 21 days), the virus (as measured by the viral load) cannot be detected in plasma. Viral RNA is the first detectable marker to appear and is the most common marker used to follow progression (Phase I). Once HIV-1 RNA reaches a certain concentration in viral load plasma, the virus can be detected using nucleic acid amplification testing (NAAT). The presence of viral RNA, absent of antibodies to HIV, confirms an acute HIV infection.
5 Alere Determine HIV-1/2 Ag/Ab Combo 5 The appearance of gag p24 protein antigen marks the next stage (Phase II) of HIV infection. During this stage where the viral load is nearing its peak, an HIV-1 infection can be characterized as either acute or early as follows 4 : n Acute: appearance/detection of free (unbound) p24 antigen (no antibodies). n Acute/Early: both free p24 antigen AND HIV Ab and/or Ag/Ab complex detected. n Early: p24 antigen/hiv-antibodies complex detected (no free p24 Ag). During the next stage where the viral load has peaked and is now reaching its set-point (Phase III), the gag p24 protein antigen is only found as an antigen-antibody immune-complex present in conjunction with free HIV-1 protein antibodies detected using an enzyme-linked immunosorbent assay (ELISA). Infections in this stage can either be early/later-stage of more established HIV infection. In the next stage where the viral load plateaus (Phase IV), the gag p24 protein antigen is present only as an Ag/Ab complex. The HIV-1 protein antibodies may now be detectable. Infections in this stage can either be early/later-stage of more established HIV infection. In fact, a person with HIV infection during the acute stage, where viral load is peaking, is 43 times more infectious than someone with a more established infection. 5 This is why early screening is vital to preventing HIV.
6 Alere Determine HIV-1/2 Ag/Ab Combo 6 Treatment of HIV 6,7 Recent studies have shown that providing early antiretroviral drug treatment for the recently infected can be beneficial for HIV patients and their uninfected sexual partners. Starting antiretroviral treatment sooner, rather than delaying therapy, may result in patients staying healthy longer. A recent study showed an increase in survival rate and life-expectancy in those treated versus untreated. Anti-retroviral initiation within the first 6 months after infection has also been associated with lower levels of T-cell activation and smaller HIV DNA and RNA reservoir size during long-term therapy. Another benefit of early therapy is in preventing transmission of HIV to others. By reducing the viral load during the highly infectious early-stages of infection, transmission of HIV to noninfected can be reduced. Long-term viral load reduction can also help in reducing onset of HIV/AIDS-related co-morbidities leading to improved long-term health outcomes and financial benefits. There can also be a significant financial impact of treating patients earlier. Such benefits in HIV-infected patients are a result of fewer illnesses and deaths. It has been shown that the potential cost of treatment of HIV/AIDS-related infections that would have otherwise been prevented by early treatment of HIV patients outweighed the costs of antiretroviral therapy drugs. Studies have also suggested that the impact of early treatment on the reduction of HIV transmission would result in a lower burden on healthcare system and overall cost savings.
7 Alere Determine HIV-1/2 Ag/Ab Combo 7 8, 9,10,11,12 Screening recommendations USPSTF The United States Preventative Services Task Force has formed the basis of the clinical standards for many professional societies, health organizations, and medical quality review groups. They recommend the following for HIV testing: n Adolescents and adults ages n All pregnant women. n Adolescents and adults who are at increased risk of exposure. Other Organizations n The Center for Disease Control recommends that diagnostic HIV testing and opt-out HIV screening be a part of routine clinical care in all health-care settings. n The Infectious Diseases Society of America recommends routine HIV screening for all sexually active adults. n The American Academy of Family Physicians recommends that clinicians screen adolescents and adults aged years for HIV infection. 13, 14 A History of HIV diagnostic tests The first HIV diagnostic test was introduced in 1985 and was a first enzyme immunoassay (EIA) that detected HIV antibodies. These first generation assays lacked the sensitivity and specificity of current widely used tests. By using recombinant proteins or peptides to produce viral antigens, the second generation assays had increased specificity and were able to detect HIV antibodies an average of 28.5 days after infection, approximately 1 week earlier than the previous first generation assays. Third generation assays could detect both HIV-1/2 immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies and were a significant advancement in HIV diagnostic tests. They were considered to have higher sensitivity than previous generations (lab-based and rapid assays are able to detect HIV antibodies approximately 21.4 and 31.6 days after HIV infection respectively) and by 2007 they had replaced earlier assays. In 2010 advanced, fourth generation assays became available in the US, although similar assays had been utilized in other countries a decade earlier. They detected both p24 antigen and HIV-1/2 IgG and IgM antibodies simultaneously. Fourth generation assays have succeeded in significantly reducing the window of detection and the time to diagnosis. They have been shown to detect HIV as soon as 16.8 days after infection. Until very recently, with FDA approval of the first Ag/Ab combination rapid test for HIV, 4th generation Ag/Ab tests have not been able to distinguish free p24 Ag from Ag/Ab immunecomplexes. This is because the laboratory samples require a dissociation step which breaks-up any Ag/Ab complexes. The p24 measured will be from both free and dissociated p24 Ag/ Ab complexes. While this may increase the sensitivity to p24, the ability to identify acute HIV infection without use of a secondary NAAT test is lost.
8 Alere Determine HIV-1/2 Ag/Ab Combo 8 Alere Determine HIV 1/2 Ag/Ab Combo Alere Determine HIV 1/2 Ag/Ab Combo is the first FDA approved rapid point-of-care test that provides for the simultaneous and separate qualitative detection of free HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2. This enables health care providers to diagnose HIV infection earlier allowing individuals to seek medical care sooner. Intended use 15 Alere Determine HIV 1/2 Ag/Ab Combo is an in vitro, visually read, qualitative immunoassay for the simultaneous detection of Human Immunodeficiency Virus Type 1 (HIV- 1) p24 antigen (Ag) and antibodies (Ab) to HIV Type 1 and Type 2 (HIV-1 and HIV-2) in human serum, plasma, capillary (fingerstick) whole blood or venipuncture (venous) whole blood. It is intended for use as a point-of-care test to aid in the diagnosis of infection with HIV-1 and HIV-2, including an acute HIV-1 infection, and may distinguish acute HIV-1 infection from established HIV-1 infection when the specimen is positive for HIV-1 p24 antigen and negative for anti-hiv-1 and anti-hiv-2 antibodies. The test is suitable for use in multi-test algorithms designed for the statistical validation of rapid HIV test results. When multiple rapid HIV test are available, this test can be used in appropriate multi-test algorithms. Alere Determine HIV-1/2 Ag/Ab Combo is not intended for newborn screening or for use with cord blood specimens or specimens from individuals less than 12 years of age. Alere Determine HIV-1/2 Ag/Ab Combo is not intended for use in screening blood, plasma, cell, or tissue donors. CLIA Complexity: Moderate
9 Alere Determine HIV-1/2 Ag/Ab Combo 9 Alere Determine HIV 1/2 Ag/Ab Combo: HIV-1 Clinical Data 15 Sample Type Sensitivity* Specificity Serum 99.9% 99.6% Plasma 99.9% 99.7% Venous Whole Blood 99.9% 99.7% Fingerstick Whole Blood 99.9% 99.8% HIV-1 Sensitivity n Serum: The estimated sensitivity of Alere Determine Combo for serum specimens in these studies was 925/926 = 99.9% (95% confidence interval 99.4 to 100.0%). n Plasma: The estimated sensitivity of Alere Determine Combo for plasma specimens in these studies was 924/925 = 99.9% (95% confidence interval 99.4 to 100.0%). n Venous Whole Blood: The estimated sensitivity of Alere Determine Combo for venous whole blood specimens in these studies was 924/925 = 99.9% (95% confidence interval 99.4 to 100.0%). n Fingerstick Whole Blood: The estimated sensitivity of Alere Determine Combo for fingerstick whole blood specimens in these studies was 929/930 = 99.9% (95% confidence interval 99.4 to 100.0%). HIV-2 Sensitivity n The sensitivity of the Alere Determine Combo for detection of antibodies to HIV-2 in these studies was estimated to be 250/250 = 100% (95 % C.I ). Specificity n Serum: The overall specificity of Alere Determine Combo using serum specimens in these studies was estimated to be 1680/1687 = 99.6% (95% confidence interval 99.2 to 99.8%). n Plasma: The overall specificity of Alere Determine Combo using plasma specimens in these studies was estimated to be 1678/1683 = 99.7% (95% confidence interval 99.2 to 99.8%). n Venous Whole Blood: The overall specificity of Alere Determine Combo using venous whole blood specimens in these studies was estimated to be 1681/1686 = 99.7% (95% confidence interval 99.3 to 99.9%). n Fingerstick Whole Blood: The overall specificity of Alere Determine Combo using fingerstick whole blood specimens in these studies was estimated to be 1335/1337 = 99.8% (95% confidence interval 99.5 to 99.9%). Sensitivity was determined by testing specimens from individuals at high risk for HIV infection and individuals known to be infected with HIV. Specificity was determined by testing specimens from individuals at high risk for HIV infection and from individuals at low risk for HIV infection. *(95% CI = 99.6% - 100%)
10 Alere Determine HIV-1/2 Ag/Ab Combo 10 Alere Determine HIV 1/2 Ag/Ab Combo: HIV-1 Preclinical Data 15 HIV-1 p24 Antigen Detection in Culture Supernatants 15 Forty-three (43) HIV-1 culture supernatants, representing HIV-1 group M subtypes A, C, D, CRF01_AE, F, G, CRF02_AG, G/H, H, J, K, and G/A, and HIV-1 group O and group N, were tested on Alere Determine HIV-1/2 Ag/Ab Combo. Culture supernatants were diluted in HIV negative human serum before testing. Of the 43 culture supernatants, 40 tested positive for HIV-1 p24 antigen at a 1:27 dilution. One HIV-1 group O, one HIV-1 subtype H, and one HIV-1 subtype F specimen tested negative for HIV-1 p24 antigen (see Table 1). Results from this study demonstrated that Alere Determine HIV-1/2 Ag/Ab Combo can detect HIV-1 p24 antigen from subtype B and from non-b subtypes, and from HIV-1 group O and group N. Table 1: Detection of HIV-1 p24 Antigen from Group M Subtype Viral Isolate Culture Supernatants using Alere Determine HIV-1/2 Ag/Ab Combo Type and Subtype* Positive / Specimens Tested HIV-1 A 4/4 HIV-1 B 4/4 HIV-1 C 4/4 HIV-1 D 4/4 HIV-1 CRF01_AE 5/5 HIV-1 F 2/3 HIV-1 G 2/2 HIV-1 CRF02_AG 4/4 HIV-1 G/H 1/1 HIV-1 H 2/3 HIV-1 J 2/2 HIV-1 K 1/1 HIV-1 G/A 1/1 HIV-1 group O 3/4 HIV-1 group N 1/1 Total 40/43 *Culture supernatant from various isolates was spiked into negative human serum for testing
11 Alere Determine HIV-1/2 Ag/Ab Combo 11 Published Studies Data taken from Masciotra, S. et al. Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 2013 A CDC study by Masciotra was the first to evaluate the Alere Determine HIV 1/2 Ag/Ab Combo with samples collected in early stage infection. 16 The key findings included: n Alere Determine Combo is reactive 15.5 days before Western Blot, which is between 3rd & 4th generation lab IAs. Results from this study clearly define the value of the Alere Determine Combo and differentiate it from other available HIV tests. This includes not only comparisons to other rapid tests, but also to current laboratory tests such as the 4th generation Ag/Ab lab assay. n The Ab component of Alere Determine Combo detects HIV 7 days before Western Blot, sooner than some lateral flow tests and similar to flow-through RTs. n The data shows that Alere Determine Combo Ab component performs as well or better than Ab-only rapid tests currently in use in the US market. n The Ag component confers an advantage over other rapid tests in detecting early HIV infection.
12 Alere Determine HIV-1/2 Ag/Ab Combo 12 Number of Early HIV Infection Samples Identified (confirmed by NAAT) Data taken from Patel et al. Rapid HIV screening: Missed opportunities for HIV diagnosis and prevention JCV May 2012 This population study from the CDC 17 evaluated the sensitivity of rapid and 4th-generation tests for the detection of recent HIV infection. They screened approximately 100K samples of which 62 met the criteria of early HIV infection (based on positive NAAT and indeterminate or negative Ab). Of the 62 cases there was sufficient quantity to test 33 samples. Five FDA approved rapid tests demonstrated 22-33% sensitivity. The third-generation lab based assay demonstrated 57% sensitivity. The Alere Determine Combo identified 25 specimens (76%) of which 17 specimens were Ag-only positive providing diagnosis of acute infection. These findings suggest that current FDA-approved rapid tests fall short in detecting early and acute HIV infections and therefore miss the opportunity to interrupt onward HIV transmission especially when using these tests in high-risk populations. Of the 62 specimens, 33 (53%) had sufficient quantity for further testing. Because testing was done sequentially, the amount of specimen available for testing was exhausted in a few instances. n Fourth generation testing with Architect HIV Ag/Ab Combo was positive in 29 of 33 (88%) specimens. n Alere Determine Combo identified antibody or antigen (Ag) in 25 of 33 (76%) specimens n 8 specimens tested Ab positive/ag negative. n 13 specimens tested Ab negative/ag positive. n 4 specimens tested Ab positive/ag positive. n Genetic Systems HIV 1/2 + O correctly detected antibody in 19 of 33 (58%) specimens n Multispot HIV-1/HIV-2 detected 11 of 33 specimens (33%) n Clearview Complete HIV1/2 detected 8 of 27 specimens (30%) n Unigold Recombigen detected 8 of 33 specimens (24%) n Clearview HIV 1/2 STAT-PAK detected 7 of 31 specimens (23%) n OraQuick Advance Rapid HIV-1/2 detected 7 of 32 specimens (22%)
13 Alere Determine HIV-1/2 Ag/Ab Combo 13 Summary of device description and biological principle of the procedure Alere Determine HIV 1/2 Ag/Ab Combo is an immunochromatographic test for the simultaneous and separate qualitative detection of free HIV-1 p24 antigen and antibodies to HIV-1 and HIV-2. The test device is a laminated strip that consists of a Sample Pad containing monoclonal biotinylated anti-hiv-1 p24 antibody, a Conjugate Pad containing monoclonal anti-hiv-1 p24 antibody-colloidal selenium and HIV-1 and HIV-2 recombinant antigen-colloidal selenium, and a nitrocellulose membrane with an immobilized mixture of recombinant and synthetic peptide HIV-1 and HIV-2 antigens in the Lower Test Area, immobilized streptavidin in the Upper Test Area, and an immobilized mixture of anti-hiv-1 antibodies, HIV-1/2 antigens, and HIV-1 p24 recombinant antigen and anti-hiv-1 p24 monoclonal antibody in the Control Area. Lot Number Patient Identification Area Product Name Control Line Area Antigen Results Area Antibody Results Area Sampling Area
14 Alere Determine HIV-1/2 Ag/Ab Combo 14 Product Information Information Type Product Detail FOR ORDERING PLEASE CONTACT: Ordering: Method Time to results Storage conditions Lateral Flow 20 minutes 2-30 C (36-86 F) Test shelf life 15 months Sample type Fingerstick or Venous Whole blood/serum/plasma FOR TECHNICAL ASSISTANCE PLEASE CONTACT: Technical Service: Technical Service ts.scr@alere.com Ordering Information Product Alere Determine HIV-1/2 Ag/Ab Combo (25 Tests) Order Number 7D2648 Alere Determine HIV-1/2 Ag/Ab Combo (100 Tests) Alere Determine HIV-1/2 Ag/Ab Combo External Controls Fingerstick Sample Collection Kit 7D2649* 7D US199 * from date of manufacture *Not available until 2014
15 References 1. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 U.S. dependent areas HIV Surveillance Supplemental Report 2012; 17(No. 3, part A) Cohen S.M. et al. The Detection of Acute HIV-1 Infection. Journal of Infectious Disease, ; s Fiebig E.W. et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17: Pinkerton, S. D, Probability of HIV Transmission During Acute Infection in Rakai, Uganda, AIDS Behav September; 12(5): doi: /s Jain V. et. al. Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size, 1202 Journal of Infectious Disease, : guidelines/adult_hlth_main.pdf 11. Lubinski, C et al. HIV Policy: The Path Forward A Joint Position Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians, Clinical Infectious Diseases 2009; 48: Cornett J. Laboratory Diagnosis of HIV in Adults: A Review of Current Methods. CID 2013: Alere Determine HIV-1/2 Ag/Ab Combo Package Insert Rev: / Masciotra, S. et al. Performance of the Alere Determine HIV-1/2 Ag/ Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol 2013: Published online 05 August DOI: /j.jcv Patel P. et al. Rapid HIV screening: Missed opportunities for HIV diagnosis and prevention Journal of Clinical Virology May Alere Determine HIV 1/2 Ag/Ab Combo Summary of Clinical Evidence For more information, please visit alerehiv.com/us 2014 Alere. All rights reserved. The Alere Logo, Alere and Determine are trademarks of the Alere groups of companies. All other trademarks referenced are trademarks of their respective owners E-01 04/14 TAP HERE TO RETURN TO THE COVER
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere HIV Combo WHO reference number: PQDx 0243-013-00 Alere HIV Combo with product codes 7D2842, 7D2843, 7D2843SET manufactured by Alere
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationHIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch
HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd
More informationTAP HERE TO SEE THE PRODUCT
TAP HERE TO SEE THE PRODUCT Make every testing opportunity count. Acute infection accounts for 5-20% of all cases of HIV infection among persons seeking testing.1 This acute phase of infection is associated
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationHIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationAdvantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
More information1 st and 2 nd Generation EIA
HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation
More informationNew Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention
New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection
More informationThe Latest in HIV Tests: What Do the Results Mean?
The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationOverview of HIV Testing Practices and Technology
Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease
More informationPoint-of-care HIV testing
Point-of-care HIV testing Joanne Stekler, MD MPH Associate Professor University of Washington December 5, 2016 Disclaimer: The findings and conclusions in this presentation are those of the author(s) and
More informationHIV Guideline Sakchai Dettrairat
HIV Guideline 2016 Sakchai Dettrairat Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Appearance of HIV markers in early HIV
More informationSP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx 0244-055-00 OraQuick HCV Rapid Antibody Test Kit with product codes 1001-0270
More informationList the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation
Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: HIV 1/2 STAT-PAK Number: PQDx Abstract
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: HIV 1/2 STAT-PAK Number: PQDx 0007-006-00 Abstract The HIV 1/2 STAT-PAK with product code HIV101, manufactured by Chembio Diagnostic
More informationThe Evolving Landscape of HIV Prevention and Diagnosis
The Evolving Landscape of HIV Prevention and Diagnosis Jenny R. McFarlane Texas Department of State Health Services HIV/STD/TB/Viral Hepatitis Unit Is it okay if we just talk? NHAS: A Call to ACT Reduce
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Alere Determine HIV-1/2 Number: PQDx Abstract
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Alere Determine HIV-1/2 Number: PQDx 0033-013-00 Abstract The Alere Determine HIV-1/2 with product codes 1 7D2342, 7D2343 and 7D2243
More informationHIV Diagnostic Testing
In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk
More informationRoutine HIV Testing Community of Practice Session #2
Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: ABON HIV 1/2/O Tri-Line Human Immunodeficiency Virus Rapid Test Device Number: PQDx 0141-051-00 Abstract ABON HIV 1/2/O Tri-Line Human
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationCAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING
Institute of Medicine (2010) CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING Workshop on the Capacity of the Healthcare System to Identify and Provide Care for Individuals with HIV/AIDS
More informationDraft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)
Date: 6 January 2012 Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc) WHO Collaborating Centre for HIV/AIDS Diagnostic and Laboratory Support Department of Clinical Sciences
More information2006 HIV Diagnostics Survey
Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: DPP HIV 1/2 Assay WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: DPP HIV 1/2 Assay WHO reference number: PQDx 0053-006-00 DPP HIV 1/2 Assay with product code 65-9506-0, manufactured by Chembio Diagnostic
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex HIV Ag/Ab Combination Number: PQDx 0144-043-00 Abstract Murex HIV Ag/Ab Combination with product codes 7G79-09 (GE41,
More informationUnigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites Updated: February 2018 Cicely Richard Office of HIV/AIDS Updated: February 2018 Cicely Richard Office of HIV/AIDS UNIGOLD RECOMBIGEN HIV 1/2 TRAINING
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx 0159-055-00 OraQuick HIV 1/2 Rapid Antibody Test with product codes 5x4-0010
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Bioelisa HIV 1+2 Ag/Ab Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Bioelisa HIV 1+2 Ag/Ab Number: PQDx 0183-060-00 Abstract Bioelisa HIV 1+2 Ag/Ab with product codes 3000-1172 and 300-1173,
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx 0159-055-00 OraQuick HIV 1/2 Rapid Antibody Test with product codes 5x4-0010
More informationModule 3: Overview of HIV Testing Technologies
Module 3: Overview of HIV Testing Technologies Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with a basic knowledge of HIV testing and how HIV rapid test results
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Enzygnost HIV Integral 4 WHO reference number: PQDx
PQDx 0214-064-00 WHO PQDx PR April/2016, version 3.0 WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Enzygnost HIV Integral 4 WHO reference number: PQDx 0214-064-00 Enzygnost
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationHIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES
ISSUES IN BRIEF: MEMBER SURVEY OF HIV ASSAY USE ASSOCIATION OF PUBLIC HEALTH LABORATORIES MARCH 2010 HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES Twenty years ago, the Association of Public Health
More informationImmunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad
Immunologic Methods in Diagnosis of HIV Infection M Parsania, Ph.D. Tehran Medical Sciences Branch, Islamic Azad University Retroviridae Retroviruses (family Retroviridae) id ) are enveloped, single stranded
More informationThe Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013
The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 Christopher Bentsen, M.S.,RAC, FRAPS Bio-Rad Laboratories, Redmond,
More informationHUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version
1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: ADULT HIV 900 (AIDS.gov 12/31/2015) HIV Lifelong HIV (human immunodeficiency virus) is a retrovirus
More informationDiagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States
TECHNICAL REPORT Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States Jennifer S. Read, MD, MS, MPH, DTM&H, and the Committee on Pediatric AIDS ABSTRACT The objectives of
More informationHIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
More informationHIV Testing. ECHO Hep C. Judith Feinberg, MD June 22, 2017
HIV Testing ECHO Hep C Judith Feinberg, MD June 22, 2017 Overview A few basics HIV epidemiology in the US HIV testing Time course of HIV-1 infection symptoms HIV proviral DNA symptoms window period HIV
More informationThe Latest on HIV Testing. Dominika Seidman, MD MAS
The Latest on HIV Testing Dominika Seidman, MD MAS Disclosures none 2 Learning objectives At the conclusion of this session, participants should be able to Define the window periods for various HIV tests
More informationComplicated viral infections
Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: SURE CHECK HIV 1/2 Assay Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: SURE CHECK HIV 1/2 Assay Number: PQDx 0054-006-00 Abstract SURE CHECK HIV 1/2 Assay with product code HIV201, manufactured
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Uni-Gold HIV Number: PQDx Abstract
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Uni-Gold HIV Number: PQDx 0149-052-00 Abstract Uni-Gold HIV with product codes 1206502, 1206502N, 1206502E, 1206502N-100 manufactured
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere q HIV-1/2 Detect WHO reference number: PQDx 0226-032-00 Alere q HIV-1/2 Detect with product codes 270110050, 270110010 and 270300001,
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: INSTI HIV-1/HIV-2 Antibody Test Number: PQDx
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: INSTI HIV-1/HIV-2 Antibody Test Number: PQDx 0002-002-00 Abstract INSTI HIV-1/HIV-2 Antibody Test with product codes, 90-1013, 90-1010,
More informationObjectives. Seven days of separation. Clinical situation a transplant. The Donor COOMBS MD PHD 1. Laboratory Diagnosis & Monitoring of HIV Infection
Laboratory Diagnosis & Monitoring of HIV Infection An Introduction to Diagnostic HIV Testing Robert W Coombs MD, PhD, FRCPC Professor, Departments of Laboratory Medicine & Medicine University of Washington,
More informationAdventures in Discordance- HIV Testing
Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationINTEGRATING HIV SCREENING INTO ROUTINE PRIMARY CARE: A HEALTH CENTER MODEL
INTEGRATING HIV SCREENING INTO ROUTINE PRIMARY CARE: A HEALTH CENTER MODEL By Cheryl Modica, PhD, MPH, BSN NACHC Consultant The health center model has helped reduce health disparities among many poor
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Uni-Gold HIV Number: PQDx Abstract
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Uni-Gold HIV Number: PQDx 0149-052-00 Abstract Uni-Gold HIV with product codes 1206502, 1206502N, 1206502E, 1206502N-100 manufactured
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationINTEGRATING HIV AND HCV TESTING
INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access
More informationTechnical Bulletin No. 104b
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104b June 22, 2016 Update to Guidelines for Diagnosing HIV Infection CPAL s Testing Algorithm for Diagnostic HIV Testing HIV Geenius
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: First Response HIV Card Test Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: First Response HIV 1-2-0 Card Test Number: PQDx 0018-010-00 Abstract First Response HIV 1-2-0 Card Test with product codes
More informationIntegrating HIV Screening Into
MaxiMizing Third ParTy reimbursement for hiv TesTing Integrating HIV Screening Into Title X Services IntroductIon HIV screening services are a core family planning service, and all individuals aged 13-64
More informationHEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection
===========ir ~~!!~~fk li=:='========= Nirav R. Shah, M.D., M.P.H. Commissioner May 16, 2013 HEALTH Sue Kelly Executive Deputy Commissioner Re: Interim Guidelines for Laboratories on the use of a new Diagnostic
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationTechnical Bulletin No. 104a
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104a April 22, 2014 Update to Guidelines for Diagnosing HIV Infection - CPAL s Testing Algorithm for Diagnostic HIV Testing Contact:
More informationA Provider s Guide to Sustainability and Reimbursement of HIV Testing in Florida Health Care Facilities
A Provider s Guide to Sustainability and Reimbursement of HIV Testing in Florida Health Care Facilities April 2011 www.fcaetc.org www.floridaaids.org USF Center for HIV Education and Research Publication
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Alere HIV/Syphilis Duo Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Alere HIV/Syphilis Duo Number: PQDx 0179-012-00 Abstract Alere HIV/Syphilis Duo with product codes 06FK30 and 06FK35, manufactured
More informationRapid HIV Antibody Testing Update
Rapid HIV Antibody Testing Update Devery Howerton, Ph.D. Division of Laboratory Systems Centers for Disease Control and Prevention CLIAC meeting, February 15, 2007 Purpose: Why Rapid HIV Testing? An example
More informationFailure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection
Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection Carol Loring, MS Rachel Gridley Fengxiang Gao, MD, MPH NH Public Health Laboratories Concord, NH Conflicts
More informationdetection of HIV-1/2 antibodies
CVI Accepts, published online ahead of print on 18 June 214 Clin. Vaccine Immunol. doi:1.1128/cvi.153-14 Copyright 214, American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of Bio-Rad
More informationCoding for Preventive Services A Guide for HIV Providers
Coding for Preventive Services A Guide for HIV Providers Jessie Murphy, MPH and Michelle Cataldo, LCSW, April 2016 Implementation of the Patient Protection and Affordable Care Act and other regulatory
More information2.1 HIV antibody tests
Over 100 different kinds of HIV test are currently available worldwide. More are likely to become available in the future. The choice of test depends on factors including laboratory requirements, how easy
More informationBringing excellence to life
Who believes in oral HIV point-of-care tests? A summary of 3 years experience and more than 2000 OraQuick ADVANCE tests N Garrett, J Saunders, K Moir, J Zelin, C Estcourt On behalf of North East London
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationHepatitis C Virus (HCV) Antibody Test
Hepatitis C Virus (HCV) Antibody Test Instructions For Use Format: Cassette For: Catalog Number: VEL-001-HCV Specimen: Serum/Plasma * Please read the instructions carefully before use INTENDED USE Hepatitis
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationCOMPLETE HIV 1/2 NAME AND INTENDED USE RESTRICTIONS SUMMARY AND EXPLANATION OF THE TEST
COMPLETE HIV 1/2 Read this Product Insert completely before using the product. Follow the instructions carefully when performing the test as not doing so may result in inaccurate Test Results. Users of
More informationAbility to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm
Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Laurie Linley, MPH; Anne H. Peruski, MPH, PhD; Richard M. Selik, MD; Kevin P. Delaney, MPH, PhD; Alexandra
More informationDiagnosis and Management of Acute HIV
Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee
More informationArizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
More informationCDIA TM Rubella IgG/IgM Rapid Test Kit
CDIA TM Rubella IgG/IgM Rapid Test Kit Cat.No: DTSJZ024 Lot. No. (See product label) Intended Use The CDIA TM Rubella IgG/IgM Rapid Test Kit is a rapid chromatographic immunoassay for the qualitative detection
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationGeenius TM HIV 1/2 Supplemental Assay Instructions For Use
Geenius TM HIV 1/2 Supplemental Assay Instructions For Use 20 72461 16003787 (Instructions for Use) This IFU is effective beginning with Geenius TM Reader APF (Assay Protocol File) V1.3. Bio-Rad 3, boulevard
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationHAV IgM Rapid Test(Cassette)
HAV IgM Rapid Test(Cassette) Cat. No.:DTS586 Pkg.Size:25 T Intended use The HAV IgM Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of IgM antibody to Hepatitis A
More informationClinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M.
Clinical Education Initiative Support@ceitraining.org TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING Bernard M. Branson, MD 1/23/2018 Testing for HIV and HCV: What s Current and What s Coming
More informationACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004
Coulter HIV p24 1. PRINCIPLE The Human Immunodeficiency Virus Type 1 (HIV-1) is recognized as the etiologic agent of acquired immunodeficiency syndrome (AIDS). The virus is transmitted by sexual contact,
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationHIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test
More informationDETERMINE SPECIMEN REQUIREMENTS HIV-1/2 Ag/Ab Combo TESTING PROCEDURE
DETERMINE SPECIMEN REQUIREMENTS HIV-1/2 Ag/Ab Combo TESTING PROCEDURE PRINCIPLE: The Determine HIV-1/2 Ag/Ag Combo assay is a qualitative immunoassay for the simultaneous detection of Human Immunodeficiency
More informationStep-by-Step Instructions For OraQuick HCV Rapid Antibody Test
Step-by-Step Instructions For OraQuick HCV Rapid Antibody Test Complexity: WAIVED for fingerstick whole blood and venipuncture whole blood. A Certificate of CLIA Waiver is required to perform the test
More informationHIV testing has significantly improved
HIV testing: an update By Nicola Zetola, MD, and Jeffrey D. Klausner, MD, MPH HIV testing has significantly improved since the first diagnostic test in 1985. Increased understanding of HIV transmission
More informationGuidance for Industry
Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test
More information